EICHOR
● Completed
Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)
Condition: FSHD · FSHD1 · FSHD2 · Sponsor: Avidity Biosciences, Inc.
About this study
A Randomized, Double-blind, Placebo-controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of AOC 1020 Administered Intravenously to Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (17)
| University of California Los Angeles | Los Angeles, California, United States | — |
| Stanford University | Palo Alto, California, United States | — |
| University of California San Diego | San Diego, California, United States | — |
| University of Colorado | Denver, Colorado, United States | — |
| University of Florida | Gainesville, Florida, United States | — |
| Rare Disease Research | Atlanta, Georgia, United States | — |
| Kansas University Medical Center | Kansas City, Kansas, United States | — |
| University of Rochester Medical Center | Rochester, New York, United States | — |
| Duke University | Durham, North Carolina, United States | — |
| Ohio State University | Columbus, Ohio, United States | — |
| University of Pennsylvania | Philadelphia, Pennsylvania, United States | — |
| University of Texas Southwestern | Dallas, Texas, United States | — |
+ 5 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.